<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03151746</url>
  </required_header>
  <id_info>
    <org_study_id>STU00205047</org_study_id>
    <nct_id>NCT03151746</nct_id>
  </id_info>
  <brief_title>Gabapentin on Postoperative Pain Associated With Ureteroscopy and Stents Insertion</brief_title>
  <official_title>Effect of Preoperative Gabapentin on Postoperative Pain Associated With Ureteroscopy and Stents Insertion: a Double Blind, Randomized, Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study's objective is to determine the efficacy of preoperative gabapentin in relieving
      postoperative pain, reducing opioid use and improving quality of recovery in subjects
      undergoing urologic surgery.

      Investigators hypothesize that subjects receiving gabapentin will have lower pain scores,
      less opioid consumption and better quality of recovery as compared to subjects who are given
      a placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately one hour prior to induction of anesthesia in preoperative holding area all
      enrolled subjects will receive PO Acetaminophen 650 mg, the Gabapentin group will receive PO
      Gabapentin 1200 mg, while the Control group will receive PO Placebo, with a small amount of
      water.

      Upon arrival in the operating room, standard ASA monitors will be applied. Intraoperative,
      patients will receive a standardized anesthetic care. This care consists of induction with IV
      propofol 2mg/kg, IV fentanyl 2 mcg/kg (adjusted body weight), and IV rocuronium 0.6 mg/kg for
      tracheal intubation or IV succinylcholine 1mg/kg if rapid sequence induction is needed.

      For maintenance of general anesthesia, investigators will use Sevoflurane, with the goal to
      maintain BP within 20% of preoperative baseline and BIS 40-60.

      If HR &gt; 100/min and BIS 40-60 may use IV esmolol 0.5 mg/kg. If BP and/or HR &gt;20% preoperative
      baseline, and BIS 40- 60 despite above management, may titrate IV antihypertensive agents.

      For PONV prophylaxis, 30 min before end of surgery investigatorswill administer IV
      ondansetron 8mg.

      The time from end of surgery to extubation in OR will be documented with a free text note in
      the EMR.

      After extubation all patients will be transported to PACU on 2-liter Oxygen by nasal cannula,
      which will be weaned off in the PACU.

      The postoperative analgesics during Phase I of recovery in PACU will consist of IV
      Hydromorphone 0.2-0.4 mg prn pain to maintain adequate pain control (NPRS&lt;4). During Phase II
      of recovery patients will receive PO Hydromorphone 2mg tablets every 4-6 hours as needed for
      pain (NPRS â‰¥ 4) and acetaminophen: 650mg PO every 6 hours

      The following data will be collected every hour during phase I and phase II recovery:

        -  pain (NPRS)

        -  sedation (Ramsey sedation scale)

        -  dizziness (1- mild, 2- moderate, 3- severe)

        -  headache YES/No If yes: NPRS score HA

        -  respiratory depression (hypoventilation/ apnea: RR &lt; 10 bpm., desaturation: (SpO2 &lt; 90%)

        -  Sedated but still in pain (Yes/No)

        -  PONV YES/NO

        -  PONV receiving antiemetic treatment

        -  time to first opioid administration (IV hydromorphone)

        -  total amount of IV hydromorphone in PACU Phase I

        -  total amount of oral analgesic (hydromorphone) in PACU Phase II

        -  time to meet discharge criteria from PACU Phase I

        -  time to meet discharge criteria from Phase II

      Study research personnel will contact participants by phone or in the hospital at 24 hours
      and 48 hours postoperative and at approximately one week in the Urology clinic. The study
      research personnel will ask questions regarding pain (NPRS) and analgesic consumption. The
      IPSS and QOR-40 questionnaires will be administered and data will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double Blind, Randomized, Placebo Controlled Trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Blinded by using placebo or active drug supplied by Investigational Drug Pharmacy.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>48 hours opioid consumption</measure>
    <time_frame>48 hours</time_frame>
    <description>Amount of opioid use in mg 48 hours after surgical procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24 hours opioid consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>Amount of opioid use in mg 24 hours opioid consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 &amp; 48 hour Pain Burden</measure>
    <time_frame>24 and 48 hours</time_frame>
    <description>Pain scores using an 11 point numeric pain rating scale 0=no pain 10 = severe pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study drug side effects</measure>
    <time_frame>24 and 48 hours</time_frame>
    <description>Gabapentin related side effects as identified at 24, 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPSS scores</measure>
    <time_frame>24 hours, 48 hours and 1 week</time_frame>
    <description>Evaluate urinary symptoms using the International Prostate Symptom Score (IPSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOR 40 scores</measure>
    <time_frame>24 hours, 48 hours and 1 week</time_frame>
    <description>Evaluate quality of recovery using the Quality of Recovery 40 (QoR 40) questionnaire a 40 question survey scored from 40 low to 200 high (good recovery)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Anesthesia</condition>
  <condition>Urethral Obstruction</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill administered 1 hour before planned surgical procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gabapentin pill (1200mg) administered orally 1 hour prior to planned surgical procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill administered orally 1 hour before planned surgical procedure</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Gabapentin pill (1200mg) administered orally 1 hour before planned surgical procedure</description>
    <arm_group_label>Gabapentin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years to 75 years

          -  Patients with obstructive kidney stones undergoing elective ureteroscopy or cystoscopy
             with Ureteral stent placement

        Exclusion Criteria:

          -  Age less than 18 or more than 75 years

          -  Acetaminophen allergy

          -  Gabapentin allergy

          -  Hydromorphone allergy

          -  Chronic use of gabapentin

          -  History of chronic pain (Pain for &gt; than 3 months)

          -  Chronic renal insufficiency (Creatinine &gt; 1.3)

          -  Seizure disorder

          -  Psychiatric disorders (medically treated)

          -  Chronic use of anticonvulsants, antidepressants, antipsychotics (use &gt; 3 months)

          -  Antacids ingested within 2 hours prior to surgery

          -  History of gastric or duodenal ulcer

          -  Pregnant or lactating

          -  Inability to communicate in English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luminita Turneau, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luminita Turneau, M.D.</last_name>
    <phone>312-695-0061</phone>
    <email>l-tureanu@northwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert McCarthy, PharmD</last_name>
    <phone>312-695-4976</phone>
    <email>r-mccarthy@northwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luminita Turneau, M.D.</last_name>
      <phone>312-695-0061</phone>
      <email>l-tureanu@northwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Robert McCarthy, PharmD</last_name>
      <phone>312-695-4976</phone>
      <email>r-mccarthy@northwestern.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG, Barry MJ. Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol. 2003 Mar;169(3):1065-9; discussion 1069.</citation>
    <PMID>12576847</PMID>
  </reference>
  <reference>
    <citation>Koprowski C, Kim C, Modi PK, Elsamra SE. Ureteral Stent-Associated Pain: A Review. J Endourol. 2016 Jul;30(7):744-53. doi: 10.1089/end.2016.0129. Epub 2016 May 23. Review.</citation>
    <PMID>27125392</PMID>
  </reference>
  <reference>
    <citation>Schmidt PC, Ruchelli G, Mackey SC, Carroll IR. Perioperative gabapentinoids: choice of agent, dose, timing, and effects on chronic postsurgical pain. Anesthesiology. 2013 Nov;119(5):1215-21. doi: 10.1097/ALN.0b013e3182a9a896. Review.</citation>
    <PMID>24051389</PMID>
  </reference>
  <reference>
    <citation>Mason CJ. High frequency jet ventilation through a Robertshaw double lumen tube. Anaesthesia. 1986 Mar;41(3):330.</citation>
    <PMID>3963344</PMID>
  </reference>
  <reference>
    <citation>Bala I, Bharti N, Chaubey VK, Mandal AK. Efficacy of gabapentin for prevention of postoperative catheter-related bladder discomfort in patients undergoing transurethral resection of bladder tumor. Urology. 2012 Apr;79(4):853-7. doi: 10.1016/j.urology.2011.11.050. Epub 2012 Feb 4.</citation>
    <PMID>22309784</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Luminita M. Tureanu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Urethral Obstruction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

